MiNK Therapeutics, Inc. INKT
MiNK Therapeutics, Inc. ("we," "our," or "MiNK") is focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T ("iNKT") cells. Amid a broader industry renaissance in innate immunity—highlighted by surging investment and clinical activity in NK, γδ T, and iNKT-based therapies—iNKT cells represent a distinct T cell ("T") population that uniquely bridges innate and adaptive immunity. They combine durable memory responses characteristic of adaptive T cells with rapid, MHC-independent rapid cytolytic capabilities of natural killer ("NK") cells. This dual functionality enables direct tumor killing via CD1d and stress ligands, potent orchestration of the tumor microenvironment through activation of dendritic cells and NK cells, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function—all while naturally suppressing graft-versus-host disease ("GvHD"). This unique combination positions iNKT cells as an optimal platform for allogeneic therapy, given their natural homing capabilities, tumor clearance potential, and efficacy against infected cells.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $5.8M | $6.3M | $15.5M | $23.1M | $14.0M | $9.5M | — |
| SG&A | $6.7M | $4.3M | $7.4M | $7.8M | $4.6M | $1.3M | — |
| Operating income | -$12.6M | -$11.3M | -$22.9M | -$30.9M | -$28.4M | -$14.6M | — |
| Interest expense | $110.0K | $93.0K | $28.0K | $253.3K | $2.4M | $2.4M | — |
| Net income | -$12.5M | -$10.8M | -$22.5M | -$28.0M | -$30.2M | -$16.2M | — |
| EPS, basic | -2.93 | -2.86 | -6.54 | -0.83 | -1.16 | — | — |
| EPS, diluted | -2.93 | -2.86 | -6.54 | -0.83 | -1.16 | -0.67 | — |
| Shares, diluted (wtd. avg.) | 4.3M | 3.8M | 3.4M | 33.7M | 26.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.4M | $4.6M | $3.4M | $19.6M | $38.9M | $2.7M | $299.0K |
| Total current assets | $13.8M | $5.0M | $3.6M | $20.4M | $39.6M | $4.1M | — |
| Property, plant and equipment | $390.9K | $732.9K | $954.0K | $1.1M | $606.6K | $458.4K | — |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M | $4.6M | — |
| Accounts payable | $3.4M | $2.7M | $3.9M | $5.8M | $3.0M | $3.1M | — |
| Total current liabilities | $13.0M | $7.0M | $11.4M | $12.7M | $16.5M | $14.2M | — |
| Retained earnings | -$156.7M | -$144.2M | -$133.4M | -$110.9M | -$82.9M | -$52.7M | — |
| Total equity | -$14.2M | -$19.6M | -$18.1M | -$401.3K | $23.8M | -$53.9M | -$36.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$9.6M | -$15.8M | -$18.9M | -$12.8M | -$8.3M | — |
| Depreciation and amortisation | $181.7K | $215.4K | $204.6K | $121.7K | $78.0K | $55.1K | — |
| Stock-based compensation | $2.7M | $1.8M | $3.9M | $3.0M | $1.7M | $87.8K | — |
| Capital expenditure | — | — | $73.6K | $250.0K | $249.0K | $95.2K | — |
| Investing cash flow | — | — | -$73.6K | -$250.0K | -$249.0K | -$95.2K | — |
| Financing cash flow | $14.7M | $10.8M | -$407.2K | -$155.6K | $49.3M | $11.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-134813.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$16.2M | -$30.2M | -$28.0M | -$22.5M | -$10.8M | -$12.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |